Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) and Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.
Analyst Ratings
This is a summary of current recommendations and price targets for Barinthus Biotherapeutics and Ayala Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Barinthus Biotherapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ayala Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Barinthus Biotherapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 261.99%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Ayala Pharmaceuticals.
Volatility & Risk
Earnings and Valuation
This table compares Barinthus Biotherapeutics and Ayala Pharmaceuticals’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Barinthus Biotherapeutics | $802,000.00 | 107.25 | -$73.35 million | ($1.92) | -1.15 |
| Ayala Pharmaceuticals | $10,000.00 | 591.25 | -$48.07 million | ($7.98) | -0.07 |
Ayala Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Barinthus Biotherapeutics and Ayala Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Barinthus Biotherapeutics | N/A | -35.19% | -30.80% |
| Ayala Pharmaceuticals | N/A | -3,967.23% | -339.10% |
Insider & Institutional Ownership
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Barinthus Biotherapeutics beats Ayala Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
